https://www.salamancapress.com/2025/03/31/kazia-therapeutics-announces-sale-of-intellectual-property-and-trademarks-rights-for-cantrixil/
Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil -...
Apr 2, 2025 - Kazia to receive USD $1 million from Vivesto for the intellectual property and trademark assets rights to the oncology drug candidate, Cantrixil
intellectual property
https://www.finanznachrichten.de/nachrichten-2026-03/67935726-vivesto-ab-first-dogs-dosed-in-vivesto-s-pk-toxicology-study-with-cantrixil-399.htm
Vivesto AB: First dogs dosed in Vivesto's PK/toxicology study with Cantrixil
Solna, Sweden, March 13, 2026 - Vivesto AB, an oncology-focused development company, today announces that the first dogs have been dosed in the company's...
in s